Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

Affiliations

• ¹ Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Philadelphia, Pennsylvania USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; Philadelphia, Pennsylvania USA.
• ² Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Philadelphia, Pennsylvania USA.
• ³ Service d'Hématologie Biologique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP); Paris, France; INSERM, UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
• ⁴ INSERM, UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France; Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP); Paris, France.
• ⁵ Pediatric Hematology Unit, L'Archet Hospital, CHU Nice; Nice, France.
• ⁶ Department of Pathology, St Jude Children's Research Hospital; Memphis, Tennessee, USA.
• ⁷ Department of Leukemia, The University of Texas MD Anderson Cancer Center; Houston, Texas, USA.
• ⁸ Department of Pediatric Hematology/Immunology, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP); Paris, France.
• ⁹ Pediatric Hematology Unit, L'Archet Hospital, CHU Nice; Nice, France; Université de Cote d'Azur, INSERM, C3M; Nice, France.
• ¹⁰ Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Philadelphia, Pennsylvania USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; Philadelphia, Pennsylvania USA; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine; Philadelphia, Pennsylvania USA. tasians@chop.edu.